Meta‐analysis of head‐to‐head clinical trials comparing incretin‐based glucose‐lowering medications and basal insulin: An update including recently developed glucagon‐like peptide‐1 ( GLP ‐1) receptor agonists and the glucose‐dependent insulinotropic polypeptide/ GLP ‐1 receptor co‐agonist tirzepatide
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Objective: To assess comparative efficacy, safety and tolerability of injectable incretin‐based glucose‐lowering medications (IBGLMs) versus basal insulin treatment in patients with type 2 diabetes. Research Design and Methods: We performed an updated meta‐analysis of randomized clinical trials of head‐to‐head comparisons of IBGLMs (short‐ and long‐acting glucagon‐like peptide‐1 [GLP‐1] receptor agonists [GLP‐1RAs] and glucose‐dependent insulinotropic polypeptide [GIP]/GLP‐1 receptor co‐agonist tirzepatide) versus basal insulin using a PubMed database search (April 2022). The primary endpoint was difference in reduction of glycated haemoglobin (HbA 1c ) versus baseline between pooled IBGLMs (fixed‐effects meta‐analysis) and their subgroups (random‐effects meta‐analysis) versus basal insulin treatment (mean differences). Secondary endpoints were fasting plasma glucose, body weight, HbA 1c target achievement, hypoglycaemia, blood pressure and lipids. Risk of bias assessment was performed using Jadad scores and the Risk of Bias tool 2.0. Results: In all, 20 studies, representing 47 study arms and 11 843 patients, were eligible. Compared with basal insulin, IGBLMs lowered HbA 1c by 0.48 (0.45‐0.52)% more than did basal insulin treatment. This effect was driven by pooled long‐acting GLP‐1RAs (ΔHbA 1c −0.25 [−0.38; −0.11]%) and the only GIP/GLP‐1 receptor co‐agonist, tirzepatide (pooled doses; ΔHbA 1c −0.90 [−1.06; −0.75]%), while short‐acting GLP‐1RAs were equally effective compared with basal insulin ( P = 0.90). All IBGLM subgroups achieved significantly lower body weight versus insulin treatment (−4.6 [−4.7; −4.4] kg), in particular tirzepatide (−12.0 [−13.8; −10.1] kg). IBGLMs significantly reduced hypoglycaemia and blood pressure and improved lipid variables. Risk of bias was low. IBGLM treatment was associated with more nausea, vomiting and diarrhoea and study medication discontinuation. Conclusions: Recently introduced, highly effective IBGLMs were superior to basal insulin treatment, reinforcing the recommendation that IBGLMs should be considered as the first injectable treatment for most patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“Our meta-analysis confirms the general superiority over basal insulin treatment of IBGLMs in controlling body weight (Figure S4), the lack of a clinically relevant general difference between short- and long-acting GLP-1RAs,(1,2) the more effective lowering of body weight with semaglutide as compared with other GLP-1RA…”
ResultGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“The present results should apply to a sizable subpopulation of all type 2 diabetes patients, as approximately 22% to 35% of representative cohorts with type 2 diabetes are treated with insulin,27 with a recent tendency to increase.28,29 If a majority of these patients are candidates for a prescription of GLP-1RAs or a…”
BackgroundSelf-citationBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 1×
“GLP-1RA treatment, as a rule,(1,2,8) and more so, tirzepatide treatment,(3,4,7) reduces body weight, however, with substantial inter-individual variation,(9) while basal insulin treatment is instead associated with some weight gain.(10) This makes incretinbased medications the preferred choice if a major therapeutic a…”
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“There is limited evidence that basal insulin treatment may reduce postprandial glycaemic excursions at all,(23) but certainly, IBGLMs do so as the result of decelerated gastric emptying,(24,25) augmented insulin secretory and suppressed glucagon responses.(26) Our meta-analysis confirms the general superiority over ba…”
ResultLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639 · cited 3×
“…q.d. Short-acting GLP-1 RAs exenatide 10 µg b.i.d. * -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5 GIP/GLP-1 R Co-Ags DelPrato et al. 2021 c DelPrato et al. 2021 b DelPrato et al. 2021 a Ludvik et al. 2021 c Ludvik et al. 2021 b Ludvik et al. 2021 a All GLP-1 RAs GIP/GLP-1 receptor co-agonist and all GLP-1 RAs [”
MethodResultInfluentialDahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597 · cited 1×
“Our meta-analysis confirms the general superiority over basal insulin treatment of IBGLMs in controlling body weight (Figure S4), the lack of a clinically relevant general difference between short- and long-acting GLP-1RAs,(1,2) the more effective lowering of body weight with semaglutide as compared with other GLP-1RA…”
ResultTrends in Prevalence and Control of Diabetes in the United States, 1988–1994 and 1999–2010
Selvin, E., Parrinello, C. M., Sacks, D. B., & Coresh, J. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2411 · Cited by 532
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetologia · doi:10.1007/s00125-019-05039-w · Cited by 487 · cited 3×
“These results, among other reasons, led the writing group of a consensus statement on the treatment of type 2 diabetes commissioned by the ADA and the EASD to recommend GLP-1RAs as the preferred treatment over (basal) insulin for the majority of patients with type 2 diabetes needing injectable glucose-lowering treatme…”
BackgroundResult
Research works printed but not linked: 15
- 10.1016/S0140-6736(21)02188-7 · DOI · Paper page
- 10.1007/s00125-018-4729-5 · DOI · Paper page
- 10.1111/dom.12804 · DOI · Paper page
- 10.1111/dom.13506 · DOI
- 10.1016/S2213-8587(17)30085-2 · DOI · Paper page
- 10.1186/s12933-022-01604-7 · DOI · Paper page
- 10.1016/0197-2456(95)00134-4 · DOI · Paper page
- 10.1136/bmj.d5928 · DOI · Paper page
- 10.1016/S0140-6736(21)01324-6 · DOI · Paper page
- 10.1111/dom.12540 · DOI
- 10.1055/a-0972-9700 · DOI
- 10.1186/s12933-018-0728-6 · DOI · Paper page
- 10.1186/s12889-021-10381-z · DOI
- 10.1007/s13300-019-00698-9 · DOI
- 10.1186/s12933-021-01344-0 · DOI · Paper page
Cited by
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Self-citationOprea, A. D., Ostapenko, L. J., Sweitzer, B., Selzer, A., Irizarry-Alvarado, J. M., Hurtado Andrade, M. D., Mendez, C. E., Kelley, K. D., Stewart, E., Fernandez Robles, C. R., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.001 · Cited by 104
Tirzepatide: A Review in Type 2 Diabetes
France, N. L., & Syed, Y. Y. (2024) · Drugs · doi:10.1007/s40265-023-01992-4 · Cited by 51
Polyagonists in Type 2 Diabetes Management
Dissanayake, H. A., & Somasundaram, N. P. (2024) · Current Diabetes Reports · doi:10.1007/s11892-023-01530-2 · Cited by 8
Hoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
“These values are consistent with earlier reports: de Mesquita et al. observed a pooled reduction of −11.8 kg (95% CI − 17.4 to −6.2) across RCTs of tirzepatide, while Nauck et al. reported a reduction of −12.0 kg (95% CI − 13.8 to −10.1) compared with insulin [39,40].”
Influential
Metadata
- Authors
- Nauck, M. A., Mirna, A. E. A., & Quast, D. R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2023-02-08
- Volume
- 25
- Issue
- 5
- Pages
- 1361-1371
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4318066343
- Cited by
- 32
- References
- 16
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meta‐analysis of head‐to‐head clinical trials comparing incretin‐based glucose‐lowering medications and basal insulin: An update including recently developed glucagon‐like peptide‐1 ( GLP ‐1) receptor agonists and the glucose‐dependent insulinotropic polypeptide/ GLP ‐1 receptor co‐agonist tirzepatide. https://app.cochat.ai/papers/10.1111/dom.14988
- The paper
- Nauck, M. A., Mirna, A. E. A., & Quast, D. R. (2023). Meta‐analysis of head‐to‐head clinical trials comparing incretin‐based glucose‐lowering medications and basal insulin: An update including recently developed glucagon‐like peptide‐1 ( GLP ‐1) receptor agonists and the glucose‐dependent insulinotropic polypeptide/ GLP ‐1 receptor co‐agonist tirzepatide. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14988
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.